



Financial Tear Sheet

Corporate Profile

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor). BeiGene has also in-licensed five drugs and drug candidates, including three marketed drugs in China ABRAXANE®, REVLIMID® and VIDAZA® under an exclusive license from Celgene Corporation, and two clinical-stage drug candidates with development and commercialization rights in China and other selected countries in the Asia-Pacific region.

BeiGene was established in Beijing in 2010 and listed on the U.S. NASDAQ Global Select Market in February 2016. As of July 2018, the Company had a global team of over 1,300 employees. BeiGene operates as a fully-integrated global biotechnology company with broad capabilities, both in China and globally, spanning research, clinical development, manufacturing and commercialization.

Primary IR Contact

Investor Relations
E-mail:
ir@beigene.com

Stock Information

BGNE (American Depositary Shares)

Exchange	NASDAQ GS (US Dollar)
Price	\$139.01

Change (%)	▲ 0.08 (0.06%)
Volume	229,834
52 Week High	\$220.10
52 Week Low	\$105.19
Market Cap	\$107,304,417,153
Rolling EPS	-9.61
PE Ratio	0
Shares Outstanding	772,363,184

Data as of 02/20/19 4:00 p.m. ET

Press Releases

February 19, 2019

[BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma](#)

February 13, 2019

[BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong](#)

February 7, 2019

[BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum – Oncology Day](#)

SEC Filings

Filing Date	Form
02/13/19	SC 13G/A
02/12/19	SC 13G
02/12/19	SC 13G/A
01/23/19	8-K

Upcoming Events

Date	Title
27 Feb 2019 6:00 p.m. ET	Q4 2018 BeiGene, Ltd. Earnings Conference Call
28 Feb 2019 2:30 p.m. HKT	Hong Kong Investor Event Location: Location: Island Shangri-La, Hong Kong, Level 5, Ballroom A

Corporate Governance

Governance Documents

-  [Code of Business Conduct and Ethics](#)
-  [Corporate Governance Guidelines](#)
-  [Securityholder Communication Policy](#)

Committee Charters

-  [Audit Committee](#)
 -  [Compensation Committee](#)
 -  [Nominating and Corporate Governance Committee](#)
-

Data provided by Nasdaq. Minimum 15 minutes delayed.

© 2016 BeiGene. All Rights Reserved.